BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 16627989)

  • 21. Selective inhibition of ADAM metalloproteases blocks HER-2 extracellular domain (ECD) cleavage and potentiates the anti-tumor effects of trastuzumab.
    Liu X; Fridman JS; Wang Q; Caulder E; Yang G; Covington M; Liu C; Marando C; Zhuo J; Li Y; Yao W; Vaddi K; Newton RC; Scherle PA; Friedman SM
    Cancer Biol Ther; 2006 Jun; 5(6):648-56. PubMed ID: 16627988
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ADAM10 is upregulated in melanoma metastasis compared with primary melanoma.
    Lee SB; Schramme A; Doberstein K; Dummer R; Abdel-Bakky MS; Keller S; Altevogt P; Oh ST; Reichrath J; Oxmann D; Pfeilschifter J; Mihic-Probst D; Gutwein P
    J Invest Dermatol; 2010 Mar; 130(3):763-73. PubMed ID: 19865098
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of ADAM10 and ADAM17 Inhibitors on Natural Killer Cell Expansion and Antibody-dependent Cellular Cytotoxicity Against Breast Cancer Cells
    Pham DH; Kim JS; Kim SK; Shin DJ; Uong NT; Hyun H; Yoon MS; Kang SJ; Ryu YJ; Cho JS; Yoon JH; Lee JS; Cho D; Lee SH; Park MH
    Anticancer Res; 2017 Oct; 37(10):5507-5513. PubMed ID: 28982863
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ADAM9 inhibition increases membrane activity of ADAM10 and controls α-secretase processing of amyloid precursor protein.
    Moss ML; Powell G; Miller MA; Edwards L; Qi B; Sang QX; De Strooper B; Tesseur I; Lichtenthaler SF; Taverna M; Zhong JL; Dingwall C; Ferdous T; Schlomann U; Zhou P; Griffith LG; Lauffenburger DA; Petrovich R; Bartsch JW
    J Biol Chem; 2011 Nov; 286(47):40443-51. PubMed ID: 21956108
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ADAM10 is the constitutive functional sheddase of CD44 in human melanoma cells.
    Anderegg U; Eichenberg T; Parthaune T; Haiduk C; Saalbach A; Milkova L; Ludwig A; Grosche J; Averbeck M; Gebhardt C; Voelcker V; Sleeman JP; Simon JC
    J Invest Dermatol; 2009 Jun; 129(6):1471-82. PubMed ID: 18971959
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ADAM-10 and -17 regulate endometriotic cell migration via concerted ligand and receptor shedding feedback on kinase signaling.
    Miller MA; Meyer AS; Beste MT; Lasisi Z; Reddy S; Jeng KW; Chen CH; Han J; Isaacson K; Griffith LG; Lauffenburger DA
    Proc Natl Acad Sci U S A; 2013 May; 110(22):E2074-83. PubMed ID: 23674691
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells.
    Zhang C; Duan X; Xu L; Ye J; Zhao J; Liu Y
    Breast Cancer Res Treat; 2012 Dec; 136(3):739-48. PubMed ID: 23117856
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The transcription factor PAX2 regulates ADAM10 expression in renal cell carcinoma.
    Doberstein K; Pfeilschifter J; Gutwein P
    Carcinogenesis; 2011 Nov; 32(11):1713-23. PubMed ID: 21880579
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor.
    Osipo C; Patel P; Rizzo P; Clementz AG; Hao L; Golde TE; Miele L
    Oncogene; 2008 Aug; 27(37):5019-32. PubMed ID: 18469855
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of ADAM10 as a major TNF sheddase in ADAM17-deficient fibroblasts.
    Mezyk-Kopeć R; Bzowska M; Stalińska K; Chełmicki T; Podkalicki M; Jucha J; Kowalczyk K; Mak P; Bereta J
    Cytokine; 2009 Jun; 46(3):309-15. PubMed ID: 19346138
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
    Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
    Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor cell-derived Timp-1 is necessary for maintaining metastasis-promoting Met-signaling via inhibition of Adam-10.
    Schelter F; Grandl M; Seubert B; Schaten S; Hauser S; Gerg M; Boccaccio C; Comoglio P; Krüger A
    Clin Exp Metastasis; 2011 Dec; 28(8):793-802. PubMed ID: 21789719
    [TBL] [Abstract][Full Text] [Related]  

  • 33. EphrinA/EphA-induced ectodomain shedding of neural cell adhesion molecule regulates growth cone repulsion through ADAM10 metalloprotease.
    Brennaman LH; Moss ML; Maness PF
    J Neurochem; 2014 Jan; 128(2):267-79. PubMed ID: 24117969
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Suppression of tunicamycin-induced CD44v6 ectodomain shedding and apoptosis is correlated with temporal expression patterns of active ADAM10, MMP-9 and MMP-13 proteins in Caki-2 renal carcinoma cells.
    Kim YH; Jung JC
    Oncol Rep; 2012 Nov; 28(5):1869-74. PubMed ID: 22923171
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy.
    Lee-Hoeflich ST; Crocker L; Yao E; Pham T; Munroe X; Hoeflich KP; Sliwkowski MX; Stern HM
    Cancer Res; 2008 Jul; 68(14):5878-87. PubMed ID: 18632642
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A disintegrin and metalloproteinase (ADAM)-mediated ectodomain shedding of ADAM10.
    Parkin E; Harris B
    J Neurochem; 2009 Mar; 108(6):1464-79. PubMed ID: 19183255
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ectodomain shedding of TNF-alpha is enhanced by nardilysin via activation of ADAM proteases.
    Hiraoka Y; Yoshida K; Ohno M; Matsuoka T; Kita T; Nishi E
    Biochem Biophys Res Commun; 2008 May; 370(1):154-8. PubMed ID: 18355445
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of MEL-18 Amplification in Anti-HER2 Therapy of Breast Cancer.
    Lee JY; Joo HS; Choi HJ; Jin S; Kim HY; Jeong GY; An HW; Park MK; Lee SE; Kim WS; Son T; Min KW; Oh YH; Kong G
    J Natl Cancer Inst; 2019 Jun; 111(6):609-619. PubMed ID: 30265336
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Compelling P1 substituent affect on metalloprotease binding profile enables the design of a novel cyclohexyl core scaffold with excellent MMP selectivity and HER-2 sheddase inhibition.
    Burns DM; Li YL; Shi E; He C; Xu M; Zhuo J; Zhang C; Qian DQ; Li Y; Wynn R; Covington MB; Katiyar K; Marando CA; Fridman JS; Scherle P; Friedman S; Metcalf B; Yao W
    Bioorg Med Chem Lett; 2009 Jul; 19(13):3525-30. PubMed ID: 19457660
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ADAM10 mediates ectodomain shedding of the betacellulin precursor activated by p-aminophenylmercuric acetate and extracellular calcium influx.
    Sanderson MP; Erickson SN; Gough PJ; Garton KJ; Wille PT; Raines EW; Dunbar AJ; Dempsey PJ
    J Biol Chem; 2005 Jan; 280(3):1826-37. PubMed ID: 15507448
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.